Filing Flows › BridgeBio Pharma (BBIO) › Q1 2025
BridgeBio Pharma (BBIO) Q1 2025 earnings results (first quarter 2025)
10-Q filed Apr 29, 2025
BridgeBio Pharma (BBIO) reported revenue of $117M for the first quarter 2025 (Q1 2025), -45% from a year earlier and up 20-fold from the quarter before. Operating margin was -89.5%, net loss $170M (145.4% of revenue).
BridgeBio Pharma, Q1 2025: revenue $117M (-45% year over year), operating margin -89.5%, net loss $170M, operating cash flow −$199M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $117M | 20× | -45% |
| Operating profit | −$104M | — | — |
| Net earnings | −$170M | — | — |
| Operating cash flow | −$199M | — | — |
What changed
Revenue was $116.6M in Q1 2025, down 45% year over year and up 1883% from the previous quarter. License and Services Revenue was the largest line at 69% of revenue. License and Services Revenue lost $131.2M year over year (down 62%), 139% of the total change.
Operating costs exceeded revenue by $104.4M, an operating margin of -89.5%. Total costs grew 5% against a revenue fall of 45%. The fastest-growing cost line was Cost of revenue (+341%). The quarter ended with a net loss of $169.6M, narrower than the previous quarter's $267.4M loss. Minority interests bore $2.2M of it: to shareholders the quarter was a loss of $167.4M.
Operating cash flow was −$199.2M. Non-cash charges added back $1.3M of depreciation and amortization and $25.9M of share-based compensation. Working capital and other items used $56.8M.
Questions
What was BridgeBio Pharma's revenue in the first quarter 2025?
BridgeBio Pharma (BBIO) reported revenue of $117M for the first quarter 2025 (Q1 2025), -45% from a year earlier and up 20-fold from the quarter before.
Was BridgeBio Pharma profitable in the first quarter 2025?
Operating loss was $104M (-89.5% of revenue) and net loss $170M.
Source: BridgeBio Pharma 10-Q on SEC EDGAR.